Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Poor cf. nothing to gloat about today.
2 trades premarket
Date/Time Price Shares Exch/Mkt
10/03/2022 8:01:23 EDT I 20.45 4 CBOE EDGX
10/03/2022 7:44:45 EDT W 19.12 1610
10:44:28 $ 19.81 120,000
Will we see higher volume due to quarter end adjustments?
Avid Bioservices to Participate in RBC Global CDMO Conference
September 27 2022 - 04:05PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the RBC Global CDMO Conference. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the conference, which will take place October 3-4, 2022.
Details of the company’s participation are as follows:
RBC Global CDMO Conference
Conference Date: October 3-4, 2022
Fireside Chat Time/Date: 12:15 - 12:45 p.m. Eastern on Monday, October 3, 2022
Format: Virtual conference; webcast available
To listen to the webcast of the RBC fireside chat please visit: http://ir.avidbio.com/investor-events.
Agreed.
Higher than normal volume today.
Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations
September 22, 2022 at 8:05 AM EDT
Download PDF
Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility Expansion Projects
TUSTIN, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Michael Alston, Jr. as vice president, operations. Mr. Alston was promoted from Avid’s director of project engineering, a role in which he led all of the company’s ongoing facility expansions. In his new position, he will continue to oversee these projects including the Myford South expansion, as well as the construction of Avid’s new dedicated cell and gene therapy facility.
Mr. Alston has more than 15 years of experience spanning operational and capital management responsibilities supporting cGMP manufacturing, facilities, engineering, and environmental, health and safety (EHS) functions. Prior to joining Avid in 2019, Mr. Alston was associate director, engineering and facilities with Sterogene Bioseperations, where he led the biotechnology company’s engineering, facilities, maintenance, safety and environmental functions. During this time, he led the design, construction and launch of Sterogene’s new, more than $5 million cGMP laboratory and pilot plant manufacturing facility. Mr. Alston has also previously served in senior roles within Merck’s viral vaccine manufacturing unit, including senior manufacturing supervisor. His career has included senior engineering, facilities and operational management positions with Unilever and ConAgra Foods.
“Michael’s promotion to vice president, operations, is well deserved based on the exceptional job he has done leading and overseeing our multiple facility expansion and buildout projects, which are complex and occurring concurrently. His extensive background in both engineering and operations is ideally suited for his new role and the responsibilities that come with the position. We are thrilled to be able to promote such a talented individual from within Avid to this key role and look forward to Michael’s continued contributions to the company’s success,” said Nick Green, president and chief executive officer of Avid Bioservices.
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
RBC Capital Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
In a report released on September 16, Sean Dodge from RBC Capital maintained a Buy rating on Avid Bioservices (CDMO – Research Report), with a price target of $22.00. The company’s shares closed yesterday at $17.15.
Dodge covers the Technology sector, focusing on stocks such as Signify Health, OptimizeRx, and GoodRx Holdings. According to TipRanks, Dodge has an average return of -2.4% and a 45.03% success rate on recommended stocks.
Avid Bioservices has an analyst consensus of Moderate Buy, with a price target consensus of $22.00.
See Insiders’ Hot Stocks on TipRanks >>
CDMO market cap is currently $1.06B and has a P/E ratio of 9.72.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CDMO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avid Bioservices, Inc. engages in the commercial manufacturing which focuses on biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. The firm specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions, and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.
Buy vol 938K vs. 350K sell
https://ih.advfn.com/stock-market/NASDAQ/avid-bioservices-CDMO/trades
Buy volume 173K sell 123K
Anyone listen to the Morgan Stanley presentation today?
Since we are attending the Morgan Stanley HC Conf, maybe they will put out a rec like they did for HALO this morning:
Morgan Stanley suggests that investors who are looking for safety in a volatile market might consider investing in this biotechnology stock. Andrew Galler, analyst at Morgan Stanley, began coverage of Halozyme Therapeutics. The company was given an overweight rating and a price target of $50. Galler described the company as a “safe port” in a storm. He wrote that Halozyme was the most defensive name we covered due to its established royalty business, long term potential for growth and diversified base business through its acquisition of Antares. Galler specifically sees value and diversification in Halozyme’s revenue streams. He emphasized Enhanze’s drug delivery technology platform. This platform is being used by major biopharmaceutical companies such as Pfizer and Bristol-Myers Squibb. Morgan Stanley’s $50 price target indicates that shares could rise 26% after Thursday’s close. He wrote that “While we don’t see any significant upside drivers other than continued expansion of Enhanze portfolio, and commercial executions by partners in near-term”, he said. — CNBC’s Michael Bloom contributed to this report.”
For 1 share.
According to Seeking Alpha:
Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M
Sep. 06, 2022 4:20 PM ETAvid Bioservices, Inc. (CDMO)By: Dania Nadeem, SA News Editor
Avid Bioservices press release (NASDAQ:CDMO): Q1 GAAP EPS of $0.02 beats by $0.01.
Revenue of $36.7M (+19.3% Y/Y) beats by $3.26M.
Shares -1.6%.
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments
September 6, 2022 at 4:05 PM EDT
Download PDF
-- Recorded First Quarter Revenue of $36.7 Million --
-- Signed $41 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $157 Million --
-- Facilities and Capabilities Expansions in Mammalian and Cell and Gene Therapy Businesses Continue on Schedule --
TUSTIN, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2022.
Highlights from the Quarter Ended July 31, 2022, and Other Events:
“Following a very strong fiscal 2022, revenues in the first quarter of fiscal 2023 established a new high. This was driven by our commercial team’s success in attracting new business, as well as the exceptional performance of our manufacturing and operations team in consistently delivering high quality product on time to our customers. I continue to be impressed by the talent and dedication of our employees, who are largely responsible for the many successes that the company has achieved to-date, and I look forward to this growing team continuing to push this business to new levels in the coming years,” stated Nick Green, president and chief executive officer of Avid Bioservices.
“Essential to our success has been our new commercial team. Over the last year, we have made substantive changes to our commercial organization, including significantly expanding our sales team, with additions supporting both our mammalian and our cell and gene therapy businesses. This new team is working exceptionally well together, and focusing on ensuring Avid’s continued growth. During the quarter, our team signed $41 million in new project orders, with a significant portion coming from new customers, and as a result, pushed Avid’s backlog to a new record high of $157 million.
“During the period, the expansion projects for both our mammalian and our cell and gene therapy businesses advanced according to plan. In the first quarter, the company achieved an important milestone with respect to our cell and gene therapy expansion, with the launch of the analytical and process development capabilities for this business. With respect to our mammalian cell business facilities expansion, the second phase of this project is ongoing, and we remain on track to begin customer projects in Myford South during the first quarter of calendar 2023.
“We believe that fiscal 2023 will be transformational for Avid, and look forward to reporting many exciting milestones ahead.”
Financial Highlights and Guidance
The company is reiterating full year revenue guidance for fiscal 2023 of $140 million to $145 million, a 17-21% increase over fiscal 2022.
Revenues for the first quarter of fiscal 2023 were $36.7 million, representing a 19% increase compared to $30.8 million recorded in the prior year period. The increase in revenues for the quarter can be primarily attributed to an increase in manufacturing revenues as compared to the prior year period.
As of July 31, 2022, revenue backlog was $157 million, representing a net increase of 43% compared to $110 million at the end of first quarter fiscal 2022. The company expects to recognize the majority of this backlog over the next twelve months.
Gross margin for the first quarter of fiscal 2023 was 25%, compared to a gross margin of 37% for the first quarter of fiscal 2022, which benefited from the receipt of unutilized capacity fees of $3.3 million. Excluding the prior year’s margin benefit from unutilized capacity fees, and the current quarter’s increase in costs associated with the establishment of our cell and gene therapy business and ahead of our mammalian capacity expansions, including the company’s increasing headcount and incremental depreciation from recently released facility expansions, our first quarter gross margin was on par with the prior year period.
Selling, general and administrative expenses (“SG&A”) for the first quarter of fiscal 2023 were $6.4 million, an increase of 42% compared to $4.5 million recorded for the first quarter of fiscal 2022. The increase in SG&A for the first quarter was primarily due to compensation and benefit expenses, facility and related expenses, and legal and accounting fees.
Net income was $1.6 million for the first quarter of fiscal 2023, which for the first time starting in fiscal 2023 includes a provision for income taxes as reported within the company’s income statement, as compared to a net income of $6.3 million for the first quarter of fiscal 2022.
Diluted earnings per share was $0.02 for the first quarter of fiscal 2023, compared to $0.10 for the first quarter of fiscal 2022.
Avid reported $115.1 million in cash and cash equivalents as of July 31, 2022, compared to $126.2 million on April 30, 2022.
More detailed financial information and analysis may be found in Avid Bioservices’ Quarterly Report on Form 10-Q, which will be filed with the Securities and Exchange Commission today.
Recent Corporate Developments
The company’s commercial team signed multiple new orders during the first quarter, totaling approximately net $41 million. A significant portion of these orders are with new customers, contributing to the ongoing expansion and diversification of the company’s client base. These orders span all areas of the business, from process development to commercial manufacturing.
The company recently announced the appointment of Pramthesh (Prem) Patel, Ph.D., as vice president, process development for Avid’s mammalian cell business. Dr. Patel is an accomplished biopharmaceutical industry executive with more than 30 years of experience and a track record of success in developing manufacturing processes for clinical trial material and commercial supplies. Dr. Patel’s career is highlighted by extended tenures supporting research, development and manufacturing activities at GSK and Bristol Myers Squibb.
The company continues to make progress with both the Myford South expansion, as well as the construction of its new dedicated cell and gene therapy facility. During the quarter, the company announced plans to expand process development capacity for the mammalian cell business. Avid estimates that this expansion will cost approximately $6 million and, depending on the mix of customer orders, has the potential to support up to an additional $20 million in annual process development revenue. The company currently expects to complete the second phase of its Myford South expansion, which includes both upstream and downstream CGMP manufacturing suites, during the first quarter of calendar 2023. With respect to the cell and gene therapy business, the company brought its process and analytical development capacity online in June 2022. The company remains on track to bring the CGMP manufacturing suites online in mid-calendar 2023. Please visit the Avid website Facilities page for more information about the company’s expansions and videos documenting progress (https://avidbio.com/expansion-updates/).
In an effort to appropriately staff our new capacities and capabilities, the company plans to continue increasing headcount through the fiscal year-end. At the end of the first quarter of fiscal 2023, the company had 343 full-time employees. This represents a 28% increase compared to 269 full-time employees as of the prior year period.
Avid Bioservices Appoints Pramthesh (Prem) Patel, Ph.D., as Vice President, Process Development for Mammalian Cell Business
September 1, 2022 at 8:05 AM EDT
Download PDF
Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb
TUSTIN, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Pramthesh (Prem) Patel, Ph.D., as vice president, process development for its mammalian cell business. Dr. Patel is an accomplished biopharmaceutical industry executive with more than 30 years of experience and a track record of success in developing manufacturing processes for clinical trial material and commercial supplies. His career is highlighted by extended tenures supporting research, development and manufacturing activities at GSK (formerly known as GlaxoSmithKline) and Bristol Myers Squibb.
Prior to joining Avid, Dr. Patel spent more than 23 years at GSK, most recently serving as senior director. In this role he managed the team responsible for the company’s mammalian cell culture and microbial fermentation process development for biopharmaceuticals. While at GSK, he was also chairperson of the technology and platform progression review committee, as well as a member of the team responsible for establishing the overall growth strategy for the company’s entire biopharmaceutical CMC development division. Dr. Patel also spent more than a decade with Bristol Myers Squibb, most recently as group leader responsible for designing and developing new and innovative mechanism-based screens adaptable to ultra-high throughput and aimed at discovering novel pharmacophores. Dr. Patel began his career as a postdoctoral scholar at Virgina Tech University. He earned a Ph.D. in microbial and cellular physiology from the University of Florida.
“Prem has spent more than 30 years helping drive innovation in the areas of biopharmaceutical research, development and manufacturing, serving in key leadership roles at two of the most successful global pharmaceutical companies. His recent work at GSK, spanning technology transfer, process scale-up, characterization and validation, and media optimization, is particularly relevant to our mammalian cell process development activities and will offer Avid great insight into how we can best serve our current and future Big Pharma customers. We are delighted to add his technical expertise and Big Pharma perspective to our team as we continue efforts to strategically grow our mammalian cell business,” said Nick Green, president and chief executive officer of Avid Bioservices.
Avid recently announced plans for further expanding its process development capacity for its mammalian cell business. As part of these efforts, Avid is expanding its state-of-the-art laboratories which could support an additional $20 million in annual process development revenue, doubling the company’s current process development capacity. The company anticipates that this expansion will be completed by the end of first calendar quarter in 2023.
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Forward-Looking Statements
Statements in this press release, which are not purely historical, including statements regarding Avid Bioservices' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the expansion of the process development laboratories may experience delays. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2022, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this press release except as may be required by law.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
The pps always gets driven down before a big buy. It hasn’t shown up on Fintel yet.
Unusual to have a trade of more than a handful of shares premarket.
08/31/2022 7:18:14 EDT W 16.97 428
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022
August 30, 2022 at 4:05 PM EDT
Download PDF
TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2023 on September 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.
About Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Primary Logo
Re: CTLT:
$CTLT UBS Lowers Catalent PT To $132 From $145; Jefferies To $110 From $130; Morgan Stanley To $120 From $132, Overweight Rating ; Deutsche Bank To $105 From $110, Hold Rating; Barclays To $115 From $130, Overweight; Part
It is likely we’ll get a PR this week re: earnings.
Buy volume 115K vs sell 88 K.
Short interest was down 600K
CDMO Short Interest
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
08/15/2022 5,258,632 498,551 10.547832
07/29/2022 5,847,931 654,696 8.932285
07/15/2022 5,625,037 613,358 9.170887
06/30/2022 5,473,663 730,595 7.492062
06/15/2022 5,934,343 501,265 11.838734
05/31/2022 5,975,789 682,625 8.754131
05/13/2022 5,690,114 902,350 6.305884
04/29/2022 6,140,786 598,982 10.252038
04/14/2022 5,372,582 537,012 10.004585
03/31/2022 5,187,666 536,756 9.66485
03/15/2022 5,459,629 590,291 9.249047
Plug up 15% on green hydrogen deal with Amazon.
Only 40 K shares traded so far.
I assume they all have d&o insurance. No doubt there are good reasons to do this but it rubs me the wrong way to give a pass on breach of fiduciary duty. They are getting paid for being directors, after all.
14A proxy filed. This is new:
Proposal No. 4:
Approval Of Amendment To Our Restated Certificate Of Incorporation To Limit The Liability Of Certain Officers
The Board has unanimously adopted a resolution to amend our Restated Certificate of Incorporation (“Charter”), subject to stockholder approval, to provide for the elimination or limitation of monetary liability of specified executive officers of the Company for breach of the duty of care. Article VI of our Charter currently provides for the Company to limit the monetary liability of directors in certain circumstances pursuant to and consistent with Section 102(b)(7) of the General Corporation Laws of Delaware (“DCGL”). Effective August 1, 2022, Section 102(b)(7) of the DCGL was amended to permit a corporation’s certificate of incorporation to include a provision eliminating or limiting monetary liability for certain senior corporate officers for breach of the fiduciary duty.
If the stockholders approve this Proposal at the Annual Meeting, the Company will file a Certificate of Amendment of Restated Certificate of Incorporation (the “Amendment”) in the form attached hereto as Appendix A.
Purpose and Possible Effects of the Proposed Amendment
The Board desires to amend its Charter to maintain provisions consistent with the governing statutes contained in the DCGL and believes that amending its Charter to add the authorized liability protection for certain officers, consistent with the protection in the Charter currently afforded its directors, is necessary in order to continue to attract and retain experienced and qualified officers.
The proposed Amendment would allow for the exculpation of certain officers only in connection with direct claims brought by stockholders, including class actions, but would not eliminate officers’ monetary liability for breach of fiduciary duty claims brought by the corporation itself or for derivative claims brought by stockholders in the name of the corporation. As is currently the case with directors under our Charter, the Amendments would not limit the liability of officers for: any breach of the duty of loyalty to the corporation or its stockholders, any acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law, and any transaction from which the officer derived an improper personal benefit.
Vote Required
Approval of the Amendment the affirmative vote of the holders of a majority of the voting power of the shares of our outstanding stock entitled to vote on this Proposal, voting together as a single class. Abstentions and broker non-votes will have the same effect as votes “AGAINST” this Proposal.
Recommendation of the Board of Directors
THE BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE APPROVAL OF THE AMENDMENT.
Unusual to have ask size of 3400 at 18.91. Usually it is only 100 or so.
They still hold 6 mil shares.
Wellington started a new position with 226 K shares.
Institutional Shares (Long) 72,900,451 - 117.90% (ex 13D/G) -
Was anything said about Groton yesterday?
What about Groton?
Jason Few, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, Aug, 11, 2022 at approximately 12:30 p.m. ET.
Few will provide a corporate and solution overview during the 25 minute presentation.
To register and attend the session, visit https://wsw.com/webcast/canaccord76/fcel/2419326 A replay and transcript will be available shortly after the event.
My 17.60 buy yesterday looks pretty good right now. I’m surprised HALO isn’t doing better.
HALO apparently had good numbers. Up 4.17 AH. Hopefully we’ll be up tomorrow as well.
I do.
HALO is taking a beating, down almost $2. They have earnings after the close.
It didn’t work last time. Hopefully today will be different.
FuelCell Energy CEO Jason Few to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 09 2022 - 08:54AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
FuelCell Energy, Inc., (Nasdaq: FCEL) -- a global leader in manufacturing stationary fuel cell energy platforms for decarbonizing power, and producing hydrogen to enable a world empowered by clean energy, today announced that company President and CEO, Jason Few, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, Aug, 11, 2022 at approximately 12:30 p.m. ET.
Few will provide a corporate and solution overview during the 25 minute presentation.
To register and attend the session, visit https://wsw.com/webcast/canaccord76/fcel/2419326 A replay and transcript will be available shortly after the event.
The Canaccord Genuity Annual Growth Conference brings together institutional investors from across the globe with some of the best and most promising growth companies in Technology, Healthcare & Life Sciences, Sustainability, Industrials, and Consumer & Retail.
About FuelCell Energy
FuelCell Energy, Inc. (NASDAQ: FCEL): FuelCell Energy is a global leader in sustainable clean energy technologies that address some of the world’s most critical challenges around energy, safety and global urbanization. As a leading global manufacturer of proprietary fuel cell technology platforms, FuelCell Energy is uniquely positioned to serve customers worldwide with sustainable products and solutions for businesses, utilities, governments and municipalities. Our solutions are designed to enable a world empowered by clean energy, enhancing the quality of life for people around the globe.
Contact:
FuelCell Energy
FuelCell@escalatepr.com
Primary Logo
08/09/2022 7:14:09 EDT I 19.97 5 NSD